Hormonal
Mendelian randomization analysis confirms a causal relationship between diabetes and an increased risk of coronary artery disease, independent of other risk factors like lipids and BMI.
If you have diabetes or high blood sugar, managing your glucose levels is crucial for protecting your heart. Genetic evidence suggests that long-term control of blood sugar can reduce the risk of coronary artery disease. Work with your healthcare provider to find a sustainable glucose management plan.
These Mendelian randomization analyses support a causal role for diabetes and its associated high glucose levels on CAD, and suggest that long-term glucose lowering may reduce CAD events.
Why this rating
High-quality genetic evidence (Mendelian randomization) using large consortia data, though observational studies showed mixed results for glucose lowering interventions.
Source
Mendelian randomization analysis supports the causal role of dysglycaemia and diabetes in the risk of coronary artery disease
Stephanie Ross et al. · European Heart Journal · 2015
DOI 10.1093/eurheartj/ehv083
More from this paper
- Genetic variants associated with HbA1c levels are linked to an increased risk of coronary artery disease, although this association is attenuated when adjusting for other cardiovascular risk factors.Moderate
- Genetic variants associated with fasting glucose (FG) levels do not show a significant independent association with coronary artery disease risk in this Mendelian randomization analysis.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →